Eli Lilly and Company (LLY) Stock Price

$873.7 0.1%

Sign up
to add to portfolio

AI Score

Hold
  • Alternative

    7
  • Fundamental

    8
  • Technical

    5

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Eli Lilly and Company, AI stock picks, stock alerts and much more.

Sign up

LLY AI Stock Analysis

Financial Performance

Eli Lilly and Company's recent financial performance shows a positive trend. The company reported revenue of $11.4B, up by 1.2% from the previous quarter and up by a significant 22.3% year over year. Their gross profit was $9.3B, also showing an increase both quarterly (1.5%) and annually (20.5%). Operating income profit was $4.4B, which is a substantial increase of 44.1% YoY and a moderate increase of 3% QoQ.

The EBITDA ratio at 0.2 indicates that the company has been generating healthy profits.

Stock Price

The stock price currently stands at $761.58, experiencing a decline of -3.5% over the last month but still significantly higher than its 200-day moving average of $839.06 which suggests potential undervaluation in the short term.

The RSI value at around 32 indicates that the stock may be oversold and can potentially rebound.

Alternative Data Signals

A look at alternative data signals reveals encouraging trends for Eli Lilly and Company's business prospects: Web traffic is growing substantially MoM (+20%) as well as YoY (+64%), reflecting increased online interest in the company; Job postings remain stable indicating steady growth; Employee outlook is highly positive with an estimated score of 83%, although slightly down YoY (-1%). Social media following across Twitter, Instagram, and Facebook are all on an upward trend reflecting growing public engagement with their brand.

Conclusion

In conclusion, despite some short-term volatility in stock price, Eli Lilly shows strong fundamentals in terms of its revenue growth, profitability and positive alternative data signals. Therefore, the outlook for Eli Lilly's stock performance is bullish.

Note: This AI Stock Analysis is based on data as of January 23. Our members can refresh and get access to an up-to-date AI stock analysis.

Sign up

Eli Lilly and Company (LLY) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Eli Lilly and Company (LLY), currently trading at $873.7, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About LLY

LSE
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide.

  • Symbol

    LLY

  • Market

    NYSE

  • Industry

    Drug Manufacturers - General

  • Market Cap

    828.4B

Similar Stocks

JNJ Johnson & Johnson
JNJ
$162.3
1.6%
6
PFE Pfizer
PFE
$26.3
1.5%
4
ABBV AbbVie
ABBV
$202.1
0.6%
6
MRK Merck & Company
MRK
$89.5
2.1%
5
NVS Novartis
NVS
$109.4
1.9%
6

LLY Alternative Data

Web Traffic

Eli Lilly and Company receives an estimated 3.9M monthly visitors to lilly.com.

  • Web Traffic

    3904645

  • Change from Previous Month

    12.3%

  • 3 Month Change

    35.3%

  • YoY Change

    35.3%

Reddit Mentions

Eli Lilly and Company has been mentioned an estimated 9 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    9

  • Daily Change

    10%

News Mentions

Eli Lilly and Company was mentioned 5 times in the news yesterday.

  • News Mentions

    5

  • Daily Change

    66.7%

  • 1 Month Change

    37.5%

  • 3 Month Change

    0%

Twitter Followers

Eli Lilly and Company has 142,732 Twitter Followers on its main Twitter (also known as X) account, which is down by -0.1% over the last month.

  • Twitter Followers

    142732

  • Daily Change

    0%

  • 1 Month Change

    0.1%

  • 3 Month Change

    0.1%

  • YoY Change

    0.1%

Facebook Engagement

Eli Lilly and Company has engaged 1,374 users via their Facebook Page over the last 7 days.

  • Facebook Engagement

    1374

  • Daily Change

    18%

  • 1 Month Change

    6.2%

  • 3 Month Change

    28.4%

  • YoY Change

    28.4%

LinkedIn Followers

1,994,620 are following Eli Lilly and Company on LinkedIn, up by 1.5% over the last month.

  • LinkedIn Followers

    1994620

  • Daily Change

    0.1%

  • 1 Month Change

    1.5%

  • 3 Month Change

    3.7%

Job Postings

Eli Lilly and Company currenly has an estimated 1,000 open job postings.

  • Job Postings

    1000

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0.7%

  • YoY Change

    0.7%

LinkedIn Employees

According to LinkedIn, Eli Lilly and Company has 47,994 employees, up by 1% over the last month.

  • LinkedIn Employees

    47994

  • Daily Change

    0%

  • 1 Month Change

    1%

  • 3 Month Change

    3.5%

  • YoY Change

    3.5%

Instagram Followers

Eli Lilly and Company has 40,921 Instagram Followers on its main Instagram account, up by 1.5% over the last month.

  • Instagram Followers

    40921

  • Daily Change

    0%

  • 1 Month Change

    1.5%

  • 3 Month Change

    3.8%

  • YoY Change

    3.8%

Business Outlook
  • Business Outlook

    83

  • Change from Previous Month

    1.2%

  • 3 Month Change

    0%

  • YoY Change

    0%

LLY Financials

LLY Key Metrics
  • Total Revenue

    $11.4B

  • Net Income

    $970.3M

  • Earnings per Share

    $1.08

  • Free cash flow

    -$458.9M

  • EBITDA

    $2.2B

  • EBITDA Ratio

    0.19651

  • Total Assets

    $75.6B

LLY 2-year Revenue & Income
LLY 2-year Free Cash Flow

LLY Technicals

LLY SMA
LLY RSI

FAQ

What's the current price of Eli Lilly and Company (LLY) Stock?
The price of an Eli Lilly and Company (LLY) share is $873.7.

What's the market cap of Eli Lilly and Company?
The current market cap of Eli Lilly and Company is 828.4B.

Should I buy or sell LLY?
Multiple alternative data signals suggest that Eli Lilly and Company stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.

Is Eli Lilly and Company a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in Eli Lilly and Company stock. The bullish indicators suggest that Eli Lilly and Company's growth prospects and market position may lead to a positive performance in the foreseeable future.

Is now a good time to buy Eli Lilly and Company (LLY) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying Eli Lilly and Company stock, given the bullish outlook.

What are some stocks similar to Eli Lilly and Company (LLY) that investors often compare it to?
Eli Lilly and Company (LLY) is often compared to similar stocks such as Johnson & Johnson, Pfizer, AbbVie, Merck & Company and Novartis.

What is the forecast for Eli Lilly and Company's stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Eli Lilly and Company's stock price to be around $941.1 in 2026. Starting from the current price of $873.7, this represents a 7.7% change in price, indicating a bullish outlook for the stock.

How to buy Eli Lilly and Company (LLY) Stock?
Eli Lilly and Company stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Eli Lilly and Company shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.